Current tools for predicting cancer-specific T cell immunity. (2nd July 2016)

• Record Type: Journal Article
• Authors: Gfeller, David; Bassani-Sternberg, Michal; Schmidt, Julien; Luescher, Immanuel F.
• Is Part Of: Oncoimmunology. Volume 5:Number 7(2016)
• Publication Date: 2016-07-02
• Subjects: Cancer -- exome -- MHC -- mutation -- peptide -- peptidome -- T cells -- transcriptome; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2016.1177691
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Tumor exome and RNA sequencing data provide a systematic and unbiased view on cancer-specific expression, over-expression, and mutations of genes, which can be mined for personalized cancer vaccines and other immunotherapies. Of key interest are tumor-specific mutations, because T cells recognizing neoepitopes have the potential to be highly tumoricidal. Here, we review recent developments and technical advances in identifying MHC class I and class II-restricted tumor antigens, especially neoantigen derived MHC ligands, including in silico predictions, immune-peptidome analysis by mass spectrometry, and MHC ligand validation by biochemical methods on T cells.